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Abstract 
Background: Bisphosphonate‑induced osteonecrosis of the jaw (BRONJ) presents with a typical pattern of jaw 
necrosis in patients who have been prescribed bisphosphonates (BPs) and other antiangiogenetic drugs to treat 
osteoporosis or bone‑related complications of cancer.
Methods: This study divided 38 patients with BRONJ into two groups according to the prescribing causes: cancer 
(n = 13) and osteoporosis (n = 25), and underwent whole exome sequencing and compared them with normal 
controls (n = 90). To identify candidate genes and variants, we conducted three analyses: a traditional genetic model, 
gene‑wise variant score burden, and rare‑variant analysis methods.
Results: The stop‑gain mutation (rs117889746) of the PZP gene in the BRONJ cancer group was significantly iden‑
tified in the additive trend model analysis. In the cancer group, ARIDS, HEBP1, LTBP1, and PLVAP were identified as 
candidate genes. In the osteoporosis group, VEGFA, DFFA, and FAM193A genes showed a significant association. No 
significant genes were identified in the rare‑variant analysis pipeline. Biologically accountable functions related to 
BRONJ occurrence‑angiogenesis‑related signaling (VEGFA and PLVAP genes), TGF‑β signaling (LTBP1 and PZP genes), 
heme toxicity (HEBP1) and osteoblast maturation (ARIDS)‑were shown in candidate genes.
Conclusion: This study showed that the candidate causative genes contributing to the development of BRONJ differ 
according to the BP dose and background disease.
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Background
Bisphosphonates (BPs) are antiresorptive agents that are 
commonly used to treat osteoporosis, multiple myeloma, 
and metastatic solid tumors [1]. BPs become internal-
ized into osteoclasts via endocytosis and subsequently 
inhibit their activity [2]. Despite BPs being well known 
to be effective in preventing osteoporotic fractures and 
preventing cancer-related side effects in bone, there has 
been a sharp decline in BP prescriptions in recent years, 
from 21.3 million in 2002 to 14.7 million in 2012 in the 
United States, with increasing reports of diverse rare but 
serious side effects associated with the use of BPs [3]. 
Osteonecrosis of the jaw (ONJ) is one of the most-serious 
and well-known side effects of BPs [4]. ONJ is character-
ized by jawbone necrosis, which exposes necrotic bones 
through holes in mucous membranes or the facial skin, 
traditionally ranging from a few millimeters to a few cen-
timeters [2, 5]. The reported incidence rate of ONJ when 
using BPs to treat cancer has ranged from 0.7 to 10.3% 
[6], while its incidence in osteoporosis has not been 
established [5, 7]. Because other drugs are also known 
to be risk factors for ONJ, such as other types of antire-
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American Association of Oral and Maxillofacial Surgeons 
committee recommended to change the nomenclature 
of ONJ caused by drugs from BRONJ (bisphosphonate-
related osteonecrosis of the jaw) to medication-related 
osteonecrosis of the jaw (MRONJ) in 2014 [8].
Apart from the well-known direct causes of MRONJ 
such as dental surgery or gingival infection, the main 
mechanism underlying the occurrence of MRONJ has 
not been clearly elucidated [9]. Since ONJ occurs only in 
specific individuals, multiple studies have been carried 
out to confirm the genetic background of MRONJ [9–11]. 
Despite the dearth of genomic studies and their results 
not being well replicated, these studies have added a deep 
pathological understanding of and insight into the devel-
opment of MRONJ, such as the patient’s innate immu-
nity, angiogenesis inhibition, osteoclast suppression, and 
systemic/local inflammations being strong predispos-
ing factors [8]. Some of the candidate genes identified 
by these studies are TGFb1, MMP2, PPARG , CYP2C8, 
VEGF, COL1A1, RANK, OPG, OPN, and RBMS3 [12–
16]. However, most of these studies were either candi-
date-gene studies or genome-wide association studies 
(GWASs) [17]. Previous whole exome sequencing (WES) 
studies have found that multiple biological pathway con-
tribute to the occurrence of MRONJ, but no specific con-
tributing genes have been identified [9]. Recently, a study 
included total 44 multiple myeloma and 17 solid tumor 
BRONJ patients of European ancestry using WES was 
identified protective SNPs with significant linkage dis-
equilibrium with SIRT1 and HERC4 genes [15, 18].
In this study we applied case–control methods that 
are commonly used in genomics research on complex 
diseases to identify genes exhibiting large variations 
between BRONJ patients and healthy control subjects. 
We divided BRONJ patients into two groups depend-
ing on whether BPs had been prescribed for cancer and 
osteoporosis, based on the assumption that the genetic 
vulnerabilities contributing to the occurrence of BRONJ 
differ between the long-term accumulation of BPs in 
osteoporosis and the high-dose toxicity of BPs in cancer.
Methods
Study design and participants
We prospectively collected clinical data and blood and 
saliva samples from 40 patients diagnosed with BRONJ: 
30 at Asan Medical Center from May 2013 to November 
2015 and 10 at Seoul St. Mary’s Hospital from November 
2010 to November 2014. All of the patients were clini-
cally evaluated by dentists and were diagnosed as BRONJ 
according to the guideline from the American Associa-
tion of Oral and Maxillofacial Surgeons [8]. All patients 
had been taken BPs or had a history of BPs prescription 
before ONJ occurs. They had necrotic lesions in maxillar 
or mandibular bone and no history of administration 
of radiation therapy at the necrotic bone area. We per-
formed sample size estimation with 70% detection power, 
20% significance level, MAF in case and MAF in 1–5% 
control, respectively, to identify variations contributing 
to BRONJ. From the calculation, 16–39 and 48–116 sam-
ples were required for the case and control respectively. 
Therefore, in this study, we started the study with 40 
cases and 90 health controls. Excluding two patients who 
were failed DNA extraction, 38 patients were included 
in the final study. BPs were prescribed for cancer (mul-
tiple myeloma or metastatic cancer) in 13 patients and 
for osteoporosis in 25 patients. The types of BPs taken 
by the patients were zoledronate (n = 11), alendronate 
(n = 10), risedronate (n = 5), pamidronate (n = 3), iban-
dronate (n = 1), zoledronate/ibandronate (n = 1), or 
unknown (n = 6). The most commonly used drug was 
zoledronate (61%, n = 8) in the cancer patients and 
alendronate (40%, n = 10) in the osteoporosis patients. 
Before the onset of BRONJ, BPs had been prescribed for 
18.1 ± 13.9  months (mean ± SD) in the cancer patients 
and 56.0 ± 52.3 months in the osteoporosis patients. The 
clinical phenotypes of the patients are listed in Table  1. 
The control subjects were enrolled for the previous study 
of “Physicians’ Seq Project” [19]. These normal control 
group was from the previous sequencing study of phy-
sicians to evaluate the physicians’ expectation and atti-
tude for pharmacogenomics using their own genome. A 
detailed description was in the previous research paper. 
The incidence of BRONJ among BP recipients was 
reported as one in 100,000, which is similar to the occur-
rence of jaw osteonecrosis (ONJ) in the general popula-
tion [7, 20, 21]. Thus, we considered that those who had 
osteoporosis but did not develop ONJ within 6 months to 
a year would not have significantly different genetic char-
acteristics than the general population.
Sequencing data analysis
The detailed methods of WES, variant calls, quality con-
trol and annotation were described in Additional file  1: 
Materials and Methods. Because the case group com-
prised subjects with two causes of disease for BP pre-
scriptions that also showed significantly different clinical 
features, we divided the cases into two subgroups: the 
BRONJ cancer group (BC, n = 13) and the BRONJ osteo-
porosis group (BO, n = 25) as shown in Additional file 1: 
Figure S1.
Because BRONJ patients in our study were mixed with 
high-dose, intravenous bisphosphonate-treated cancer 
group and low-dose, per-oral bisphosphonate-treated 
osteoporosis group, we assumed that the underlying 
mechanism of ONJ occurrence differ between the two 
groups, so divided patients into two groups according 
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their background disease and BPs dosage and compared 
each group with the normal control (n = 90). To identify 
candidate genes and variants associated with BRONJ for 
each group, we used three analytical methods. Significant 
genes/variants identified from the three methods were 
classified using gene set enrichment analysis and we 
reviewed literatures to evaluate fundamental pathophys-
iology of BRONJ. The three analysis pipeline is demon-
strated in Fig. 1.
We applied three analysis methods to identify BRONJ-
associated variants and genes. First, three different tra-
ditional genetic testing models were used to compare 
variant frequencies between the cases and controls. This 
method has a solid statistical basis but also a low statis-
tical power in detecting variants exhibiting mild effects 
and low frequencies. Second, collapsing analysis with 
the gene as a unit of measurement was used to assess the 
damaging effects of all deleterious variants in the genes. 
This is similar to other burden-based tests that collapse 
all rare and/or damaging variants within a region into a 
single value, but our method yielded a score from 0 to 1 
that reflected the variability of the variant distribution in 
a gene. The third analysis method was the rare-variant 
association test using a multiple regression model while 
adjusting covariates in order to identify rare variants that 
affect the phenotype.
Case–control test of variant frequencies
We performed a case–control association analysis with 
the variant-allele frequencies (AFs) using the SnpSift 
CaseControl tool for three different genetic models [22] 
for each BC and each BO versus controls. The statistical 
tests used were the Cochran–Armitage test for trends 
and Fisher’s exact test (FET) for the dominant and reces-
sive models. For the trend model, we applied weights of 
0, 1, and 2 for the reference homozygous, alternative het-
erozygous, and alternative homozygous variants, respec-
tively. To identify SNPs and INDELs that significantly 
impacted the function of the corresponding protein, the 
loss of function (LoF) variants defined as follows were 
used for further analysis: stop gain/loss, coding INDELs, 
splice-site acceptors, and splice-site donors. We also 
included variants predicted as damaging according to 
their SIFT [23] score and a CADD [24] score of > 20.
Gene‑based collapsing analysis
In order to measure the degree of damage of a specific 
gene, we used a previous algorithm to convert the num-
ber of a mutations in a gene into a gene score [25, 26]. 
The gene score (a gene deleteriousness score) quantified 
the impact of damage of a gene, and was defined as the 
geometric mean of the SIFT scores for the multitude of 
deleterious variants in a gene. The gene score represents 
an estimate of the aggregate impact of all deleterious 
Table 1 Clinical characteristics of the study participants
Data are mean ± SD or n (%) values
BRONJ total cases (n = 38) BRONJ cancer cases 
(n = 13)





Age, years 79.9 ± 11.7 60.1 ± 8.7 76.6 ± 8.8 41.1 ± 7.2
Males 8 (21%) 7 (53.8%) 2 (8.0%) 47 (52.2%)
Diagnosed condition resulting in BP 
prescription
–
 Cancer 13 (34.2%) 13 (100%) 0 (0%)
  Breast cancer 6 (46.2%) 6 (46.2%) –
  Multiple myeloma 5 (38.5%) 5 (38.5%) –
  Prostate cancer 2 (15.4%) 2 (15.4%) –
 Osteoporosis 25 (65.7%) – 25 (100%)
BP –
 Zoledronate 11 (29.0%) 8 (61.5%) 3 (12.0%)
 Alendronate 10 (26.0%) – 10 (40.0%)
 Residronate 5 (13.2%) – 5 (20.0%)
 Pamidronate 3 (7.9%) 3 (23.1%) –
 Ibandronate 2 (5.3%) – 2 (8.0%)
 Zoledronate/ibandronate 1 (2.6%) 1 (7.7%) –
 Unknown 6 (15.8%) 1 (7.7%) 5 (20.0%)
Duration of BP treatment before BRONJ 
occurrence, months
42.7 ± 46.3 18.1 ± 13.9 56.0 ± 52.3 –
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variants in the genes. Since the SIFT score ranges from 
0 to 1 and is lower for deleterious variants, a lower gene 
score indicates greater damage to the function of the 
gene at the protein level. We identified genes with dif-
ferent gene scores between cases and controls using 
Wilcoxon rank-sum test. For further analyzing which 
variants would be responsible for the deleteriousness of 
a specific gene, we used FET to compare the variant fre-
quencies with all SIFT-mapped variants.
Rare‑variant association analysis
To evaluate the effect of rare functional variants that were 
only observed as phenotype manifestations in one or two 
patients, we applied the sequence kernel association test 
(SKAT) for rare LoF variants [27]. The threshold for rare 
variants was a MAF < 0.5% in the Asian population of 
phase I of the 1000 Genomes [28] and the ExAC project 
[29] from the SnpSift annotation. Functionally damaging 
variants included previously defined LoF variants. Sex 
and age were used as covariates, and the threshold for 
significance was a p value of 0.1 after correcting for mul-
tiple-tests bias. We used the freely available R package to 
apply the SKAT with a small-sample option. Statistical 
analyses including multiple-tests correction were imple-
mented using custom scripts in R (v3.1.5, R Foundation 
for Statistical Computing, Vienna, Austria) [30].
Results
Variant frequency analysis
To identify genetic variants associated with BRONJ, we 
performed statistical tests with three genetic models—
dominant, recessive, and Cochran–Armitage trend mod-
els—for the two case groups (13 BC and 25 BO) versus 
90 healthy controls. Among 519,375 SNPs/INDELs and 
Fig. 1 The three analysis pipelines for identifying candidate genes and variants
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23,420 genes, we extracted 2646 SNPs/INDELs and 2327 
genes with LoF variants and performed statistical tests 
for the BC. LoF variants include stop gain/loss, coding 
INDELs, splice-site acceptors, splice-site donors, and also 
variants that were predicted as damaging according to 
both the SIFT [23] and CADD [24] scores. For BO there 
were 3684 SNPs/INDELs and 3101 genes with LoF vari-
ants out of the total of 693,497 SNPs/INDELs and 23,534 
genes. To exclude population-wise major variants that 
were likely to be benign, variants with a MAF > 0.5% in 
the Asian population from phase I of the 1000 Genomes 
Project [28] and the ExAC [29] were filtered out. This left 
343 variants in 335 genes for BC and 367 variants in 357 
genes for the BO. Using SnpSift case–control analysis, 
we performed tests for the three genetics models for all 
of these LoF variants: dominant, recessive, and additive 
trend models. After correcting for multiple-tests bias, a 
stop-gain variant in PZP for the BC versus controls was 
identified in the trend model that was associated with a 
higher BRONJ risk (Table  2). There was no significant 
variant in BO versus controls.
Gene‑score comparisons
After excluding probably benign hypervariable genes 
including transcription factors (Additional file 1: Results), 
we performed a clustering analysis using the DAVID 
Functional Annotation Clustering Tool [31] to evaluate 
common biological functions shared in these gene sets 
on 232 and 564 genes for the BC and BO, respectively. 
For functional terms mapped to the pathway databases, 
there were eight clusters for BC versus controls and seven 
for BO versus controls with a significance of p < 0.05. 
The enrichment score of each group and statistical test 
results for the BC and BO are listed in Additional file 1: 
Tables S1, S2, respectively. All of the annotated genes are 
presented in Additional file 1: Table S3.
To identify contributing variants for cases with lower 
gene scores, we performed a FET of the AF of all vari-
ants with SIFT scores of < 0.3 among the functionally 
damaging variants in the case versus control groups. 
Functionally damaging variants are defined in Additional 
file 1: Figure S2. At this step there were 10,087 and 12,952 
variants for BC and BO, respectively, among which the 
number of intersection of variants having significantly 
different gene scores were 878 and 1647, respectively. 
Then 161 variants in the BC and 444 variants in the BO 
with higher AF for cases than controls (p < 0.05, odds 
ratio > 1) were filtered in. To filter out population major 
variants and false-positive results, we excluded variants 
with lower AFs in 90 healthy controls than in the ExAC 
Asian or the 1000 Genomes Project Asian population 
(12 variants in the BC and 15 variants in the BO). After 
removing the variants with a zero allele count in the con-
trol group, six and five variants were identified and vali-
dated using IGV viewer for the BC and BO, respectively. 
From the gene-score analysis pipeline, we identified 
ARID2, CDC27, HEBP1, LTBP1, PLVAP, and TNRC18 
in the BC, and CDC27, DFFA, FAM193A, TNRC18, and 
VEGFA in the BO (Tables 3, 4). To identify the clusters 
of patients for these genes, we drew the heat map for the 
gene score (Fig. 2).
Hierarchical clustering analyses revealed the exclusive 
pattern of genes related to angiogenesis (PLVAP) and 
genes related to TGF-β signaling (LTBP1 and PZP) in the 
BC. Despite TNRC18 and CDC27 showed significant dif-
ferences in both BC and BO but those genes do not have 
definite explainable functions underlying BRONJ. In BO, 
DFFA and FAM193A genes also significantly enriched 
but do not have any known underlying function related to 
ONJ. Otherwise, VEFGA gene in BO and PLVAP, HEBP1, 
and LTBP1 gene in BC could be applied to explain the 
BRONJ mechanism. ARID2 gene showed damaged score 
in eight patients, and also known as cancer-related gene, 
but hardly having a pathophysiological relationship to 
BRONJ.
Rare‑variant association analysis
We performed the SKAT-O and burden test for BC ver-
sus controls and for BO versus controls including LoF 
variants with a MAF < 0.05% in the Asian population of 
the ExAC project and the 1000 Genomes Project phase-
I data. The total number of genes with rare LoF vari-
ants was 112 in the BC and 121 in the BO. There were 
no genes consistent with the FDR-corrected probabil-
ity criterion of p < 0.05 in either the BC or BO. For BO 
versus controls, 60 genes were significantly associated 
with the risk of BRONJ in the SKAT-O analysis with-
out multiple testing correction, and there were none 
Table 2 Results of the variant-allele-frequency association analysis in BC
a PZP, PZP, alpha-2-macroglobulin like
Chr POS rsID Ref/Alt Gene Function SIFT/CADD Genotype counts Allele frequency p value
Case (n = 13) Control (n = 90) 1KP ASN ExAC ASN
GG/GA/AA GG/GA/AA
chr12 9,333,626 rs117889746 G/A PZPa Stop gain 0.3/36 11/1/1 70/20/0 0.095 0.083 0.001
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in the burden test. The biological process GO term for 
proteolysis (GO:0006508) was significantly enriched 
(p = 0.02), with an enrichment score of 1.21, including six 
genes (ENDOU, MMP8, CPNE1, TMPRSS7, KLK10, and 
PRSS42) from the gene set enrichment analysis. There 
were no genes associated an increased or decreased risk 
of BRONJ occurrence in the BC.
Discussion
This study evaluated the genes associated with the pre-
disposition to develop BRONJ by comparing patients 
according to the reason for them being prescribed BPs 
(cancer or osteoporosis) using WES. The genes identi-
fied in our study—LTBP1, PZP, ARID2, and HEBP1 in 
osteoporosis BRON patients—clearly support the pre-
vious evidence that angiogenesis, osteoclast activity, 
bone remodeling, and immune responses are critical 
underlying mechanisms. In osteoporosis BRONJ group, 
we identified the VEGFA gene which is known to play a 
significant role in angiogenesis was also found in previ-
ous studies to be associated with the risk of ONJ [11]. 
We also identified a novel gene associated with the risk 
of BRONJ that is involved in angiogenesis in patients 
of cancer BRONJ, PLVAP, which is the VEGFA down-
stream signaling target involved in the structure of the 
diaphragm and functions in vascular fenestrations [32]. 
Other genes identified in cancer group also have ONJ 
related functions: the PZP and LTBP1 genes are involved 
in TGF-β signaling (which plays an important role in 
bone remodeling and tissue repair), the HEBP1 gene is 
involved in heme pathophysiology, and the ARID2 gene 
is involved in osteoblast differentiation. These find-
ings suggest that exposure to high-dose BPs in patients 
with cancer with dysfunctional genes with various 
underlying pathophysiologies of ONJ increase the risk 
of BRONJ occurrence. On the other hand, in the osteo-
porosis BRONJ with a relatively long-term exposure to 
BPs (42.7 ± 46.3 months), there were no more candidate 
genes to explain the pathophysiology besides VEGFA.
Previous studies investigated to identify the contribut-
ing genetic profile of BRONJ development include two 
GWAS studies [10, 33], eleven candidate gene studies 
[11–15, 17, 34–38], and two WES studies [9, 18]. Most 
of these studies were case–control studies involving less 
than one hundred single-race patients for BRONJ in 
cancer patients. The candidate genes and SNPs identi-
fied through these studies varied and rarely replicated 
in another. The pathogenesis of BRONJ is not clearly 
defined, however, some hypothesis has been suggested 
[39, 40]. First, BPs strongly inhibits the activity of osteo-
clasts and induced apoptosis of osteoclasts. This reduces 
both bone absorption and formation. Second, BPs inhibit 
angiogenesis reducing blood vessel distribution in the 
bone along with inhibiting endothelial growth factor, 
which interferes with bone remodeling and wound heal-
ing in the jaw bone. Lastly, owing to the strong affinity of 
BPs to hydroxyapatite and long half-life leads to extreme 
suppression of bone turnover as well as wound healing. 
As the results of our study suggested as well, damaged 
genes involved in different but still diverse underlying 
mechanisms might contribute to the development of 
BRONJ with diverse mechanisms especially in patients 
with distinct underlying diseases with very different dos-
age and potency of BPs.
We used three analysis pipelines to identify candidate 
genes in order to minimize the false negative caused by 
various effects of causative genes and genetic variations 
contributing to BRONJ. The statistical technique using 
Fig. 2 Heat maps showing damaged genes among the BRONJ samples
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the traditional genetic model showed that the stop-gain 
mutation (rs117889746) in exon 15 of the PZP gene was 
significantly associated with the occurrence of BRONJ 
in 2 of the 13 cancer patients (1 homozygous and 1 het-
erozygous). These two patients developed ONJ after 
receiving Zoledronate injections for 10  months and 
24  months after dental procedures such as extraction 
and implant removal. The PZP protein as a pan protease 
inhibitor is involved in the main mechanisms underlying 
the development of BRONJ: bone formation and inflam-
mation. PZP protein is similar to α2-macroglobulin and 
has a high affinity with TGF-β1 and TGF-β2. Binding by 
PZP prevents TGFs from binding to cell-surface recep-
tors, which in turn can eliminate TGF-β according to 
the morphological changes in PZP, and also act as a car-
rier [41]. TGF-β promotes tissue repair by enhancing the 
transcription of type I collagen, which is the main compo-
nent of the extracellular matrix (ECM). Previous studies 
have shown that the expression of TGF-β is significantly 
reduced in specimens obtained from patients with non-
traumatic osteonecrosis of the femoral head [42]. This is 
consistent with previous immunohistochemistry stud-
ies of the TGF-β1 signaling molecule in BRONJ patients 
showing significantly reduced TGF-β1 and Smad-2/3 in 
BRONJ patients compared to osteoradionecrosis patients 
[43]. Previous studies have shown that TGF-β promotes 
bone resorption of the mouse calvariae bone resorption 
at low doses and does not promote the resorption of the 
long bones at high doses [44]. Therefore, the results of 
our study suggest that the TGF-β signaling involved in 
ECM repair is related to the occurrence of BRONJ.
Our utilization of a gene-score analysis pipeline 
allowed us to identify more candidate genes than when 
using traditional genetic models. Excluding genes with-
out known specific functions (CDC27 and TNRC18), 
ARID2, HEBP1, LTBP1, and PLVAP were the only signifi-
cant differences in the cancer group revealed by the gene-
score methodology, while DFFA, FAM193A, and VEGFA 
were the only significant differences in the osteoporosis 
group. In particular, the VEGFA gene, which differed sig-
nificantly in the osteoporosis BRONJ, is a member of pre-
vious well known risk gene families in ONJ [12], VEGF 
which is a growth factor that plays an important role in 
angiogenesis, vasculogenesis, and epithelial cell growth 
[42]. It has long been known that VEFG plays an impor-
tant role in bone formation and repair [41], and there 
has also been a GWAS supporting the hypothesis that 
the impairment of angiogenesis in the tissue surround-
ing unnecrotized tissue would be involved in the devel-
opment of BRONJ [11]. In addition, the PLVAP gene, 
which is involved in the structure of the diaphragm and 
vascular fenestrations identified in the cancer group, 
may be a downstream target of VEGF signaling, and is 
also an important factor in angiogenesis. Otherwise, the 
LTBP1 gene that is related to osteoclast activity, which 
is involved in bone remodeling and the development of 
BRONJ, has been newly identified in this study. This gene 
has been shown to release the active form of TGF-β1 in 
the ECM [45], and it plays an important role in osteo-
genesis and bone resorption. Thus, dysfunction of the 
LTBP1 gene might also be implicated in the development 
of BRONJ. The HEBP1 gene identified in three BRONJ 
cancer patients is very interesting as well. This gene codes 
Heme Binding Protein 1 (HBP1), and heme is a complex 
of iron and tetrapyrrole protoporphyrin IX, which is in 
the prosthetic group of hemoproteins that play a key role 
in oxygen binding and the transportation of compounds 
such as hemoglobin and myoglobin [46]. An elevated 
concentration of free heme can induce pro-oxidant, pro-
inflammatory, and cytotoxic effects that affect different 
cell types. Heme toxicity plays a major role in the patho-
genesis of hemolytic disorders such as sickle-cell dis-
ease. Only a few studies have investigated the effects of 
dysfunction of the HEBP1 gene on HBP production and 
metabolism, but heme toxicity and BRONJ present with 
very similar symptoms, and so further studies are needed 
into this association.
Conclusions
We identified genes enriched significantly differ-
ent between cancer and osteoporosis BRONJ group. 
Despite the small number of patients, the genes related 
to the pathophysiology in BRONJ occurrence were more 
enriched in the cancer group than osteoporosis. The limi-
tations of our study are that we could not prove candi-
date genes and mutations derived from the study through 
additional testing besides the single ethnicity of partici-
pants (all East Asian). The results of this study need to be 
verified in future replication studies. It is well known that 
high doses of BPs increase the risk of BRONJ. Our results 
suggest that BRONJ may occur more easily in patients 
with impaired function of angiogenesis, osteoclast activ-
ity, and tissue repair with high dose BPs. If additional 
studies are conducted on a more sufficient patient popu-
lation, the conclusions of this study should be supported.
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